Madeline Slisz, PA
Physician Assistant · Amherst, NYNPI 1659961076
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,880 of the $100,899 with a category attached, or 66.3%. Neurocrine Biosciences, Inc. accounts for 62.3% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $39,213, more than ten times the $1,428 reported in 2021. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $289.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$63K
- Acadia Pharmaceuticals Inc$31K
- Teva Pharmaceuticals USA, Inc.$5K
- Otsuka America Pharmaceutical, Inc.$502
- Eisai Inc.$192
- Johnson & Johnson$168
- plus $834 from 12 others
What the payments were for
- Consulting fees$18,18818%
- Speaking & faculty fees$66,88066%
- Travel & lodging$6,5787%
- Food & beverage$8,8129%
- Education$4420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 110 | $62,892 |
| Acadia Pharmaceuticals Inc | 92 | $31,152 |
| Teva Pharmaceuticals USA, Inc. | 58 | $5,160 |
| Otsuka America Pharmaceutical, Inc. | 25 | $502 |
| Eisai Inc. | 5 | $192 |
| Johnson & Johnson | 3 | $168 |
| AbbVie | 10 | $136 |
| Lundbeck LLC | 10 | $131 |
| Sunovion Pharmaceuticals Inc. | 8 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $124 |
| Jazz Pharmaceuticals Inc. | 6 | $120 |
| Vanda Pharmaceuticals Inc. | 4 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Bausch Health US, LLC | 2 | $28 |
| Lilly USA, LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,899 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 88 | $39,240 |
| NuplazidPimavanserin Tartrate | 28 | $34,832 |
| Austedo XrDeutetrabenazine | 16 | $19,548 |
| Duloxetine Hcl | 552 | $2,836 |
| Sertraline Hcl | 357 | $2,447 |
| Divalproex Sodium | 175 | $2,275 |
| Aripiprazole | 173 | $1,597 |
| Memantine Hcl | 202 | $1,109 |
| Escitalopram Oxalate | 202 | $1,017 |
| Citalopram HbrCitalopram Hydrobromide | 94 | $945 |
| Trazodone Hcl | 228 | $944 |
| Olanzapine | 110 | $511 |
| Buspirone Hcl | 78 | $465 |
| Lurasidone Hcl | 49 | $460 |
| Lorazepam | 38 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $502 | $39,24088 claims |
| Acadia Pharmaceuticals IncNuplazid | $31,152 | $34,83228 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $5,160 | $19,54816 claims |
| Lilly USA, LLCOlanzapine | $23 | $511110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Amherst
- Michael AsbachAmherst$962K
- Rachel AllenAmherst$54K
- Lauren JendraszekAmherst$40K
- Delaney FragaleAmherst$33K
- Henry YuBronx$1M
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.